GBS, Inc. (GBS)
| Market Cap | 30.51M |
| Revenue (ttm) | 1.98M |
| Net Income (ttm) | -7.04M |
| Shares Out | 10.41M |
| EPS (ttm) | -0.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 544,775 |
| Open | 2.15 |
| Previous Close | 2.15 |
| Day's Range | 1.94 - 2.19 |
| 52-Week Range | 1.94 - 14.24 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 11, 2021 |
About GBS
GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The...
Financial Performance
In 2021, GBS, Inc.'s revenue was $1.98 million, an increase of 949.30% compared to the previous year's $188,744. Losses were -$7.04 million, 122.4% more than in 2020.
Financial StatementsNews
FDA Pre-Submission for Saliva-Based Glucose Test to Replace Invasive Finger-Prick
SYDNEY, Oct. 19, 2021 /PRNewswire/ -- The iQ Group Global Ltd (NSX.IQG), on behalf of its subsidiary, Life Science Biosensor Diagnostics Pty Ltd (LSBD), is pleased to announce that one of its licensees,...
GBS Inc. Announces its Pre-Submission package is with the FDA
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at p...
GBS Inc. to Present at Upcoming September Virtual Investor Conferences
H.C. Wainwright 23 rd Global Investor Conference: September 13 th - 15 th
Life Sciences Company GBS Develops Technology to Take the Fear out of Diabetes and COVID Testing
GBS Inc. is presenting at the Benzinga Healthcare Small Cap Conference on September 29, 2021. For some people with diabetes, testing with a pinprick is no more than a minor inconvenience.
GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-...
Hot Penny Stocks to Buy Under $5? 3 You Might Not Have Heard Of
Looking for penny stocks under $5? Check these 3 out The post Hot Penny Stocks to Buy Under $5?
Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick' Alternative in Global Glucose Monitoring Survey
Global results show 90% of patients are in favor of a saliva-based glucose test Global results show 90% of patients are in favor of a saliva-based glucose test
GBS Inc. Reports First Quarter 2021 Financial Results and Recent Business Highlights
- Anticipate Emergency Use Submission for SARS-CoV-2 Antibody Biosensor Test in the Second Half of 2021-
GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test
NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- GBS, Inc. (NasdaqGS: GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for Biolog...
GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Devel...
NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary heal...
GBS, Inc. Announces Closing of Upsized $21.6 Million Initial Public Offering
NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their prima...
2 More IPOs Make Their Trading Debuts Today
GBS and Inhibikase Therapeutics priced late Tuesday.
UPDATE - GBS Inc. Announces Pricing of $21.6 Million Initial Public Offering
Will Trade on the Nasdaq Global Market Under Ticker “GBS” Will Trade on the Nasdaq Global Market Under Ticker “GBS”
GBS Inc. Announces Pricing of Initial Public Offering
Will Trade on the Nasdaq Global Market Under Ticker “GBS”
Saliva-based glucose device developer GBS lowers deal size by 10% ahead of $18 million IPO
GBS, which is developing saliva-based tests for SARS-CoV-2 and diabetes management in China, lowered the proposed deal size for its upcoming IPO on Tuesday. The New York, NY-based company now plans to r...